These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34935033)

  • 1. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis.
    Grymonprez M; Simoens C; Steurbaut S; De Backer TL; Lahousse L
    Europace; 2022 Jul; 24(6):887-898. PubMed ID: 34935033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
    Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
    BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study.
    Grymonprez M; De Backer TL; Capiau A; Vauterin D; Mehuys E; Boussery K; Steurbaut S; Lahousse L
    Br J Clin Pharmacol; 2023 Apr; 89(4):1360-1373. PubMed ID: 36321924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
    Martinez C; Katholing A; Wallenhorst C; Freedman SB
    Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
    BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in secondary stroke and systemic embolism prevention.
    Gorczyca I; Michalska A; Chrapek M; Jelonek O; Wałek P; Wożakowska-Kapłon B
    Cardiol J; 2021; 28(6):896-904. PubMed ID: 31313276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight: a Systematic Review and Meta-Analysis.
    Grymonprez M; De Backer TL; Steurbaut S; Boussery K; Lahousse L
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):749-761. PubMed ID: 33428092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF).
    Kim H; Lee YS; Kim TH; Cha MJ; Lee JM; Park J; Park JK; Kang KW; Shim J; Uhm JS; Park HW; Choi EK; Kim JB; Kim C; Kim J; Joung B
    Korean J Intern Med; 2020 Jan; 35(1):99-108. PubMed ID: 31014064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme.
    Mazurek M; Halperin JL; Huisman MV; Diener HC; Dubner SJ; Ma CS; Rothman KJ; Healey JS; Teutsch C; Paquette M; França LR; Lu S; Bartels DB; Lip GYH
    Europace; 2020 Jan; 22(1):47-57. PubMed ID: 31651951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a single non-sex-related stroke risk factor on atrial fibrillation and oral anticoagulant outcomes: a systematic review and meta-analysis.
    Grymonprez M; Steurbaut S; De Sutter A; Lahousse L
    Open Heart; 2020 Dec; 7(2):. PubMed ID: 33361315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolic, bleeding, and mortality risks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: A population-based study.
    Lau WCY; Douglas IJ; Wong ICK; Smeeth L; Lip GYH; Leung WK; Siu CW; Cheung BMY; Mok MTC; Chan EW
    Heart Rhythm; 2020 Jan; 17(1):33-40. PubMed ID: 31377423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor.
    Potpara TS; Dagres N; Mujović N; Vasić D; Ašanin M; Nedeljkovic M; Marin F; Fauchier L; Blomstrom-Lundqvist C; Lip GY
    Adv Ther; 2017 Feb; 34(2):357-377. PubMed ID: 27933569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effects of NOAC and VKA therapy on the incidence of dementia in patients with atrial fibrillation: A systematic review and meta-analysis.
    Wang W; Fan W; Su Y; Hong K
    Clin Cardiol; 2023 Aug; 46(8):866-876. PubMed ID: 37366141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation　- The Fushimi AF Registry.
    Masunaga N; Abe M; Ogawa H; Aono Y; Ikeda S; Doi K; An Y; Ishii M; Iguchi M; Esato M; Tsuji H; Wada H; Hasegawa K; Lip GYH; Akao M;
    Circ J; 2018 Nov; 82(12):2983-2991. PubMed ID: 30381701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant Treatment in Patients with AF and Very High Thromboembolic Risk in the Era before and after the Introduction of NOAC: Observation at a Polish Reference Centre.
    Bielecka B; Gorczyca-Głowacka I; Ciba-Stemplewska A; Wożakowska-Kapłon B
    Int J Environ Res Public Health; 2023 Jun; 20(12):. PubMed ID: 37372735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K oral anticoagulants and risk of fractures: a systematic review and meta-analysis.
    Mongkhon P; Fanning L; Wong KHTW; Man KKC; Wong ICK; Lau WCY
    Europace; 2021 Jan; 23(1):39-48. PubMed ID: 33085751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation.
    Russo V; Bottino R; Rago A; Papa AA; Liccardo B; D'Onofrio A; Golino P; Nigro G
    Semin Thromb Hemost; 2020 Nov; 46(8):970-976. PubMed ID: 33105504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.